Foldrx Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for FOLDRX PHARMS, and what generic alternatives to FOLDRX PHARMS drugs are available?
FOLDRX PHARMS has two approved drugs.
There are three US patents protecting FOLDRX PHARMS drugs.
There are fifty-seven patent family members on FOLDRX PHARMS drugs in twenty-seven countries and fourteen supplementary protection certificates in thirteen countries.
Drugs and US Patents for Foldrx Pharms
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Foldrx Pharms | VYNDAQEL | tafamidis meglumine | CAPSULE;ORAL | 211996-001 | May 3, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
Foldrx Pharms | VYNDAMAX | tafamidis | CAPSULE;ORAL | 212161-001 | May 3, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
Foldrx Pharms | VYNDAQEL | tafamidis meglumine | CAPSULE;ORAL | 211996-001 | May 3, 2019 | RX | Yes | Yes | 7,214,695 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Foldrx Pharms | VYNDAMAX | tafamidis | CAPSULE;ORAL | 212161-001 | May 3, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
Foldrx Pharms | VYNDAMAX | tafamidis | CAPSULE;ORAL | 212161-001 | May 3, 2019 | RX | Yes | Yes | 7,214,696 | ⤷ Sign Up | ⤷ Sign Up | ||||
Foldrx Pharms | VYNDAQEL | tafamidis meglumine | CAPSULE;ORAL | 211996-001 | May 3, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Foldrx Pharms
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Foldrx Pharms | VYNDAQEL | tafamidis meglumine | CAPSULE;ORAL | 211996-001 | May 3, 2019 | 8,168,663 | ⤷ Sign Up |
Foldrx Pharms | VYNDAQEL | tafamidis meglumine | CAPSULE;ORAL | 211996-001 | May 3, 2019 | 8,653,119 | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Foldrx Pharms Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Taiwan | I644902 | ⤷ Sign Up |
Brazil | 0317463 | ⤷ Sign Up |
Brazil | PI0317463 | ⤷ Sign Up |
Mexico | 2017002954 | ⤷ Sign Up |
China | 100448852 | ⤷ Sign Up |
Japan | 2020055832 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Foldrx Pharms Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1587821 | CR 2012 00006 | Denmark | ⤷ Sign Up | PRODUCT NAME: TAFAMIDIS (SOM MEGLUMIN); REG. NO/DATE: EU/1/11/717/001 20111116 |
1587821 | SPC/GB12/009 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: TAFAMIDIS, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING THE MEGLUMINE SALT; REGISTERED: UK EU/1/11/717/001 20111118 |
1587821 | 6/2012 | Austria | ⤷ Sign Up | PRODUCT NAME: TAFAMIDIS; REGISTRATION NO/DATE: EU/1/11/717/001 20111116 |
1587821 | 2012/007 | Ireland | ⤷ Sign Up | PRODUCT NAME: VYNDAQEL- TAFAMIDIS MEGLUMINE; REGISTRATION NO/DATE: EU/1/11/717/001 20111116 |
1587821 | CA 2012 00006 | Denmark | ⤷ Sign Up | |
1587821 | 126 5003-2012 | Slovakia | ⤷ Sign Up | PRODUCT NAME: TAFAMIDIS MEGLUMIN; REGISTRATION NO/DATE: EU/1/11/717/001 20111116 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.